These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 28375678)
21. Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells. Castanotto D; Lin M; Kowolik C; Koch T; Hansen BR; Oerum H; Stein CA Mol Ther; 2016 Jun; 24(6):1117-1125. PubMed ID: 26961407 [TBL] [Abstract][Full Text] [Related]
22. Antisense Oligonucleotide Targeting of 3'-UTR of mRNA for Expression Knockdown. Golshirazi G; Ciszewski L; Lu-Nguyen N; Popplewell L Methods Mol Biol; 2018; 1828():91-124. PubMed ID: 30171537 [TBL] [Abstract][Full Text] [Related]
23. Efficient nuclear delivery and nuclear body localization of antisense oligo-nucleotides using degradable polymersomes. Kim Y; Tewari M; Pajeroski DJ; Sen S; Jason W; Sirsi S; Lutz G; Discher DE Conf Proc IEEE Eng Med Biol Soc; 2006; 2006():4350-3. PubMed ID: 17947079 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides. Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928 [TBL] [Abstract][Full Text] [Related]
25. Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. Hassane FS; Abes R; El Andaloussi S; Lehto T; Sillard R; Langel U; Lebleu B J Control Release; 2011 Jul; 153(2):163-72. PubMed ID: 21536086 [TBL] [Abstract][Full Text] [Related]
26. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Aartsma-Rus A; van Vliet L; Hirschi M; Janson AA; Heemskerk H; de Winter CL; de Kimpe S; van Deutekom JC; 't Hoen PA; van Ommen GJ Mol Ther; 2009 Mar; 17(3):548-53. PubMed ID: 18813282 [TBL] [Abstract][Full Text] [Related]
27. New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Touznik A; Lee JJ; Yokota T Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745 [TBL] [Abstract][Full Text] [Related]
28. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles. Liu Y; Franzen S Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455 [TBL] [Abstract][Full Text] [Related]
29. SIDT2 mediates gymnosis, the uptake of naked single-stranded oligonucleotides into living cells. Takahashi M; Contu VR; Kabuta C; Hase K; Fujiwara Y; Wada K; Kabuta T RNA Biol; 2017 Nov; 14(11):1534-1543. PubMed ID: 28277980 [TBL] [Abstract][Full Text] [Related]
30. Preclinical studies on intestinal administration of antisense oligonucleotides as a model for oral delivery for treatment of duchenne muscular dystrophy. van Putten M; Young C; van den Berg S; Pronk A; Hulsker M; Karnaoukh TG; Vermue R; van Dijk KW; de Kimpe S; Aartsma-Rus A Mol Ther Nucleic Acids; 2014 Nov; 3(11):e211. PubMed ID: 25405468 [TBL] [Abstract][Full Text] [Related]
31. Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides. Pendergraff H; Schmidt S; Vikeså J; Weile C; Øverup C; W Lindholm M; Koch T Nucleic Acid Ther; 2020 Feb; 30(1):4-13. PubMed ID: 31618108 [TBL] [Abstract][Full Text] [Related]
32. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. Aartsma-Rus A; van Ommen GJ RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229 [TBL] [Abstract][Full Text] [Related]
34. On the role of methacrylic acid copolymers in the intracellular delivery of antisense oligonucleotides. Yessine MA; Meier C; Petereit HU; Leroux JC Eur J Pharm Biopharm; 2006 May; 63(1):1-10. PubMed ID: 16364618 [TBL] [Abstract][Full Text] [Related]
35. New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration. Pasteuning-Vuhman S; Boertje-van der Meulen JW; van Putten M; Overzier M; Ten Dijke P; Kiełbasa SM; Arindrarto W; Wolterbeek R; Lezhnina KV; Ozerov IV; Aliper AM; Hoogaars WM; Aartsma-Rus A; Loomans CJ FASEB J; 2017 Jan; 31(1):238-255. PubMed ID: 27733450 [TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. 't Hoen PA; van der Wees CG; Aartsma-Rus A; Turk R; Goyenvalle A; Danos O; Garcia L; van Ommen GJ; den Dunnen JT; van Deutekom JC Pharmacogenomics; 2006 Apr; 7(3):281-97. PubMed ID: 16610940 [TBL] [Abstract][Full Text] [Related]
37. The interactions of amphiphilic antisense oligonucleotides with serum proteins and their effects on in vitro silencing activity. Felber AE; Bayó-Puxan N; Deleavey GF; Castagner B; Damha MJ; Leroux JC Biomaterials; 2012 Sep; 33(25):5955-65. PubMed ID: 22656448 [TBL] [Abstract][Full Text] [Related]
39. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397 [TBL] [Abstract][Full Text] [Related]
40. Transfection of normal primary human skeletal myoblasts with p21 and p57 antisense oligonucleotides to improve their proliferation: a first step towards an alternative molecular therapy approach of Duchenne muscular dystrophy. Endesfelder S; Bucher S; Kliche A; Reszka R; Speer A J Mol Med (Berl); 2003 Jun; 81(6):355-62. PubMed ID: 12732930 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]